Abbott Laboratories (ABT) stock analysis and fair value
ABT · NYSE · Healthcare
99,60 US$
▲ +1,13%
In 30 seconds
The business. Healthcare. Sells 44,3 B US$ a year, keeps 15% as profit and sales grow 5,1% a year (last 5 years).
Strength. Passes 7 of 8 quality checks and could repay its debt with 0,8 years of profit.
ABT fair value
Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.
See the fair valueAbbott Laboratories key numbers
- Market cap
- 172,3 B US$
- P/E (price ÷ earnings)
- 26,8
- Dividend yield
- 2,41%
- Revenue growth
- 8,7%
- a year, over 9 years
- Profit margin
- 14,7%
- Quality checks
- 7/8
Fiscal 2025 financials, as filed with the SEC.
What analysts say
Buy
25 of 33 analysts recommend buying.
See everything about ABT on Cerne
- Fair value with your own assumptions
- Every analyst and price target
- 10 years of financials in simple charts
- Dividends, earnings and ratios vs. the sector